John Simes

Summary

Affiliation: University of Sydney
Country: Australia

Publications

  1. pmc A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials
    John Simes
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia
    PLoS ONE 5:e8580. 2010
  2. doi request reprint Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration
    John Simes
    From the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia J S, A C K, R M the Division of Internal and Cardiovascular Medicine and Stroke Unit, Department of Internal Medicine, University of Perugia, Perugia, Italy C B, G A the Population Health Research Institute, McMaster University, Hamilton, ON, Canada J W E the Department of Cardiothoracic and Vascular Sciences, University of Padua, Padua P P and the Department of Haematology, South Eastern Area Laboratory Services SEALS, Prince of Wales Hospital, Sydney, Australia T A B
    Circulation 130:1062-71. 2014
  3. pmc Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation
    Lukas P Staub
    NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia
    BMC Med Res Methodol 12:12. 2012
  4. pmc The Early Prevention of Obesity in CHildren (EPOCH) Collaboration--an individual patient data prospective meta-analysis
    Lisa M Askie
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
    BMC Public Health 10:728. 2010
  5. pmc Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study
    Jisheng Cui
    World Health Organization Collaborating Centre for Obesity Prevention, Deakin University, Melbourne, Australia
    BMC Med Res Methodol 10:27. 2010
  6. doi request reprint Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial
    R John Simes
    NHMRC Clinical Trials Center, University of Sydney, Sydney, Australia
    Am Heart J 159:988-97. 2010
  7. ncbi request reprint Practical approaches to minimize problems with missing quality of life data
    R J Simes
    NHMRC Clinical Trials Centre, University of Sydney, Australia
    Stat Med 17:725-37. 1998
  8. ncbi request reprint Subgroup analysis: application to individual patient decisions
    R John Simes
    NHMRC Clinical Trials Centre, Locked Bag 77, Camperdown, NSW 2050, Australia
    Med J Aust 180:467-9. 2004
  9. doi request reprint Low-dose aspirin for preventing recurrent venous thromboembolism
    Timothy A Brighton
    Department of Haematology, South Eastern Area Laboratory Services SEALS, Prince of Wales Hospital, Sydney, Australia
    N Engl J Med 367:1979-87. 2012
  10. doi request reprint Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease
    Paul J Nestel
    From the Lipoprotein and Atherosclerosis Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Australia P J N NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia E H B, J S, M F Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia A M T Green Lane Cardiovascular Research Unit, Auckland City Hospital, Auckland, New Zealand H D W Department of Medicine, University of Queensland, Brisbane, Australia D M C Department of General and Interventional Cardiology, University Heart Centre Hamburg, Hamburg, Germany S B and Royal Prince Alfred Hospital Department of Biochemistry, Sydney, Australia D R S
    Arterioscler Thromb Vasc Biol 33:2902-8. 2013

Collaborators

Detail Information

Publications19

  1. pmc A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials
    John Simes
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia
    PLoS ONE 5:e8580. 2010
    ..The effects of fenofibrate estimated by intention-to-treat were likely to have been attenuated. We aimed to quantify this effect and to develop a method for use in other long-term trials...
  2. doi request reprint Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration
    John Simes
    From the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia J S, A C K, R M the Division of Internal and Cardiovascular Medicine and Stroke Unit, Department of Internal Medicine, University of Perugia, Perugia, Italy C B, G A the Population Health Research Institute, McMaster University, Hamilton, ON, Canada J W E the Department of Cardiothoracic and Vascular Sciences, University of Padua, Padua P P and the Department of Haematology, South Eastern Area Laboratory Services SEALS, Prince of Wales Hospital, Sydney, Australia T A B
    Circulation 130:1062-71. 2014
    ....
  3. pmc Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation
    Lukas P Staub
    NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia
    BMC Med Res Methodol 12:12. 2012
    ..There is a lack of guidance on the interpretation of this evidence, and patient management studies often neglect a discussion of the limitations of measuring patient management as a surrogate for health outcomes...
  4. pmc The Early Prevention of Obesity in CHildren (EPOCH) Collaboration--an individual patient data prospective meta-analysis
    Lisa M Askie
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
    BMC Public Health 10:728. 2010
    ..This methodology minimises the publication and selection bias often associated with a retrospective meta-analysis by allowing hypotheses, analysis methods and selection criteria to be specified a priori...
  5. pmc Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study
    Jisheng Cui
    World Health Organization Collaborating Centre for Obesity Prevention, Deakin University, Melbourne, Australia
    BMC Med Res Methodol 10:27. 2010
    ..However, in many situations, recurrent event data are frequently observed. It is inefficient to use methods for the analysis of first events to analyse recurrent event data...
  6. doi request reprint Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial
    R John Simes
    NHMRC Clinical Trials Center, University of Sydney, Sydney, Australia
    Am Heart J 159:988-97. 2010
    ..The international Hirulog and Early Reperfusion or Occlusion (HERO-2) trial of 17,073 patients with ST-segment elevation myocardial infarction provided the opportunity to explore international differences in outcomes...
  7. ncbi request reprint Practical approaches to minimize problems with missing quality of life data
    R J Simes
    NHMRC Clinical Trials Centre, University of Sydney, Australia
    Stat Med 17:725-37. 1998
    ..Since some missing data due to deteriorating health may still occur, the design should include the collection of auxiliary QOL information. Preventative strategies are illustrated with an ongoing trial in advanced breast cancer...
  8. ncbi request reprint Subgroup analysis: application to individual patient decisions
    R John Simes
    NHMRC Clinical Trials Centre, Locked Bag 77, Camperdown, NSW 2050, Australia
    Med J Aust 180:467-9. 2004
  9. doi request reprint Low-dose aspirin for preventing recurrent venous thromboembolism
    Timothy A Brighton
    Department of Haematology, South Eastern Area Laboratory Services SEALS, Prince of Wales Hospital, Sydney, Australia
    N Engl J Med 367:1979-87. 2012
    ..Patients who have had a first episode of unprovoked venous thromboembolism have a high risk of recurrence after anticoagulants are discontinued. Aspirin may be effective in preventing a recurrence of venous thromboembolism...
  10. doi request reprint Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease
    Paul J Nestel
    From the Lipoprotein and Atherosclerosis Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Australia P J N NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia E H B, J S, M F Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia A M T Green Lane Cardiovascular Research Unit, Auckland City Hospital, Auckland, New Zealand H D W Department of Medicine, University of Queensland, Brisbane, Australia D M C Department of General and Interventional Cardiology, University Heart Centre Hamburg, Hamburg, Germany S B and Royal Prince Alfred Hospital Department of Biochemistry, Sydney, Australia D R S
    Arterioscler Thromb Vasc Biol 33:2902-8. 2013
    ..Association between lipoprotein(a) (Lp(a)) level and a first-ever coronary (CHD) event is recognized. Less is evident in patients with overt CHD and stable symptoms in whom we investigated associations between Lp(a) and future events...
  11. doi request reprint Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study
    David Sullivan
    Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Sydney, NSW, Australia
    Diabetes Res Clin Pract 94:284-90. 2011
    ....
  12. doi request reprint Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes
    Philip M Clarke
    School of Public Health, University of Sydney, Sydney, New South Wales
    Med Care 47:61-8. 2009
    ....
  13. doi request reprint Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study
    Wendy E Hague
    From National Health and Medical Research Council Clinical Trials Centre, University of Sydney, New South Wales, Australia W E H, J S, A K, A C K, H P Green Lane Cardiovascular Service, Auckland City Hospital, New Zealand H D W, R A S Department of Cardiology, Royal Melbourne Hospital and University of Melbourne, Victoria, Australia D H Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia P J N Greenslopes Hospital, Brisbane, Queensland, Australia D M C Royal Prince Alfred Hospital, Sydney, New South Wales, Australia D R S University of Western Australia, Perth, Australia P L T University of Queensland, Brisbane, Queensland, Australia M W Faculty of Health Sciences and Medicine, Bond University, Queensland, Australia P P G and Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia A M T
    Circulation 133:1851-60. 2016
    ....
  14. ncbi request reprint Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis
    Val Gebski
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia
    Lancet Oncol 8:226-34. 2007
    ..We aimed to clarify the benefits of neoadjuvant chemoradiotherapy or chemotherapy versus surgery alone by a meta-analysis of randomised trial data...
  15. ncbi request reprint Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus
    Zahir H Alshehry
    From Baker IDI Heart and Diabetes Institute, Melbourne, Vic, Australia Z H A, P A M, C K B, N A M, G W, P J N, B A K, P J M King Fahad Medical City, Riyadh, Saudi Arabia Z H A Department of Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Vic, Australia Z H A, M J M, P J M NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia J S, E H B School of Public Health and Preventive Medicine, Monash University, Melbourne, Vic, Australia A M T, S Z Royal Prince Alfred Hospital, Sydney, NSW, Australia D R S Hópital Bichat Claude Bernard and Université Paris 7, Paris, France M M George Institute for Global Health, Sydney, NSW, Australia B N, N R P, S Z, Vojnomedicinska akademija
    Circulation 134:1637-1650. 2016
    ..Lipidomics enables the assessment of hundreds of lipid species as potential markers for disease risk...
  16. pmc Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
    Kathryn M Field
    Royal Melbourne Hospital, Parkville, Australia K M F, P M P, M A R, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia J S, C S B B, E H B, K S, A L Sir Charles Gairdner Hospital, Nedlands, Australia A K N School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia A K N Austin Health, Heidelberg, Australia L C, G F Royal North Shore Hospital, St Leonards, Australia H W Prince of Wales Hospital, Randwick, Australia E J H University of New South Wales, Sydney, Australia E J H Monash Medical Centre, Clayton, Australia R F Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Australia P M P, M A R, G F
    Neuro Oncol 17:1504-13. 2015
    ..The optimal use of bevacizumab in recurrent glioblastoma (GBM), including the choice of monotherapy or combination therapy, remains uncertain. The purpose of this study was to compare combination therapy with bevacizumab monotherapy...
  17. ncbi request reprint Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective
    Val Gebski
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia
    J Natl Cancer Inst 98:26-38. 2006
    ..We reanalyzed the results from 36 unconfounded trials (i.e., addition of radiation therapy was the sole discriminant between treatments being compared) that were identified in previous meta-analyses, which provided 38 comparisons...
  18. ncbi request reprint Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study
    Roland Stocker
    Centre for Vascular Research, School of Medical Sciences, University of New South Wales, UNSW, Sydney, NSW 2052, Australia
    Atherosclerosis 187:198-204. 2006
    ..This study confirms that pravastatin lowers plasma CoQ10 concentrations, but this does not appear to predict the risk of recurrent CVD events...
  19. pmc Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk
    Hueiming Liu
    The George Institute for International Health, PO Box M201, Missenden Road, NSW 2050, Australia
    BMC Public Health 10:458. 2010
    ....